The Breast Cancer Association Consortium (BCAC) has been established to conduct combined case-control analyses with augmented statistical power to try to confirm putative genetic associations with breast cancer. We genotyped nine SNPs for which there was some prior evidence of an association with breast cancer: CASP8 D302H (rs1045485), IGFBP3 -202 C A (rs2854744), SOD2 V16A (rs1799725), TGFB1 L10P (rs1982073), ATM S49C (rs1800054), ADH1B 3' UTR A G (rs1042026), CDKN1A S31R (rs1801270), ICAM5 V301I (rs1056538) and NUMA1 A794G (rs3750913). We included data from 9–15 studies, comprising 11,391–18,290 cases and 14,753–22,670 controls. We found evidence of an association with breast cancer for CASP8 D302H (with odds ratios (OR) of 0.89 (95% confidence interval (c.i.): 0.85–0.94) and 0.74 (95% c.i.: 0.62–0.87) for heterozygotes and rare homozygotes, respectively, compared with common homozygotes; P_trend = 1.1 10^-7) and weaker evidence for TGFB1 L10P (OR = 1.07 (95% c.i.: 1.02–1.13) and 1.16 (95% c.i.: 1.08–1.25), respectively; P_trend = 2.8 10^-5). These results demonstrate that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies.

NOTE: In the version of this article initially published, there was an error that affected the calculations of the odds ratios, confidence intervals, between-study heterogeneity, trend test and test for association for SNP ICAM5 V301I in Table 1 (ICAM5 V301I); genotype counts in Supplementary Table 2 (ICAM5; ICR_FBCS and Kuopio studies) and minor allele frequencies, trend test and odds ratios for heterozygotes and rare homozygotes in Supplementary Table 3 (ICAM5; ICR_FBCS and Kuopio studies). The errors in Table 1 have been corrected in the PDF version of the article. The errors in supplementary information have been corrected online.

1. Sheffield University Medical School, Sheffield S10 2RX, UK.
2. Department of Oncology and Department of Public Health and Primary Care, University of Cambridge, Cambridge CB2 1TN, UK.
3. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland 20852, USA, and Core Genotyping Facility, Advanced Technology Center, National Cancer Institute, Gaithersburg, Maryland 20892, USA.
4. Cancer Center and M. Sklodowska-Curie Institute of Oncology, 02-781 Warsaw, Poland.
5. Nofer Institute of Occupational Medicine, 90-950 Lodz, Poland.
6. University of Melbourne, Melbourne, Victoria 3010 Australia.
7. University of Otago, Dunedin, New Zealand.
8. Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria 3053, Australia.
9. The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK, and London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
10. Department of Clinical Biochemistry, and Department of Breast Surgery, Herlev University Hospital, University of Copenhagen, 2730 Herlev, Denmark.
11. Deutsches Krebsforschungszentrum, 69120 Heidelberg, Germany.
12. Dr. Margarete Fischer Bosch Institute of Clinical Pharmacology, D-70376 Stuttgart, Germany, and University of Tübingen, 72074 Tübingen, Germany.
13. German Cancer Research Center, 69120 Heidelberg, Germany.
14. University of Ulm, 89069 Ulm, Germany.
15. Department of Gynecology and Obstetrics, 30625 Hannover, Germany.
16. Department of Radiation Oncology, Hannover Medical School, 30625 Hannover, Germany.
17. Departments of Obstetrics and Gynecology, FIN-00290 Helsinki, Finland.
18. Department of Oncology, Helsinki University Central Hospital, FIN-00290 Helsinki, Finland.
19. Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK.
20. National Cancer Institute, 10400 Bangkok, Thailand.
21. International Agency for Research on Cancer, 69372 Lyon, France.
22. Queensland Institute of Medical Research, Brisbane, Queensland 4029, Australia.
23. Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, FI-70211 Kuopio, Finland, and Departments of Oncology and Pathology, University Hospital of Kuopio, FI-70211 Kuopio, Finland.
24. Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
25. Netherlands Cancer Institute, Departments of Experimental Therapy, Epidemiology and Molecular Pathology, 1066 CX Amsterdam, The Netherlands.
26. Seoul National University College of Medicine, Seoul 151-742, Korea.
27. National Cancer Center, Goyang 411769, Korea.
28. Department of Surgery, Ulsan University College of Medicine, Ulsan 680-749, Korea.
29. Department of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-171 77 Stockholm, Sweden.
30. Population Genetics, Genome Institute of Singapore, Singapore 138672.
31. Spanish National Cancer Research Centre, (CNIO), E-28029 Madrid, Spain.
32. National Cancer Institute, US National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, Maryland 20892, USA, and University of Minnesota, Division of Environmental Health Sciences, Minneapolis, Minnesota 55455, USA.
33. These authors contributed equally to this work.

Correspondence to: Angela Cox^1,33 e-mail: a.cox@shef.ac.uk

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NPG Journals

by Subject Area

• Chemistry

  • Chemistry
  • Drug discovery
  • Biotechnology
  • Materials
  • Methods & Protocols

• Clinical Practice & Research

  • Cancer
  • Cardiovascular medicine
  • Dentistry
  • Endocrinology
  • Gastroenterology & Hepatology
  • Methods & Protocols
  • Pathology & Pathobiology
  • Urology

• Earth & Environment

  • Earth sciences
  • Evolution & Ecology

• Life sciences

  • Biotechnology
  • Cancer
  • Development
  • Drug discovery
  • Evolution & Ecology
  • Genetics
  • Immunology
  • Medical research
  • Methods & Protocols
  • Microbiology
  • Molecular cell biology
  • Neuroscience
  • Pharmacology
  • Systems biology

• Physical sciences

  • Physics
  • Materials

by A - Z Index